193 related articles for article (PubMed ID: 19335276)
1. CXCR4 chemokine receptor antagonists: perspectives in SCLC.
Burger JA; Stewart DJ
Expert Opin Investig Drugs; 2009 Apr; 18(4):481-90. PubMed ID: 19335276
[TBL] [Abstract][Full Text] [Related]
2. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
3. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer.
Hartmann TN; Burger M; Burger JA
J Biol Regul Homeost Agents; 2004; 18(2):126-30. PubMed ID: 15471215
[TBL] [Abstract][Full Text] [Related]
4. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
Burger M; Glodek A; Hartmann T; Schmitt-Gräff A; Silberstein LE; Fujii N; Kipps TJ; Burger JA
Oncogene; 2003 Nov; 22(50):8093-101. PubMed ID: 14603250
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Hartmann TN; Burger JA; Glodek A; Fujii N; Burger M
Oncogene; 2005 Jun; 24(27):4462-71. PubMed ID: 15806155
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
Burger JA; Peled A
Leukemia; 2009 Jan; 23(1):43-52. PubMed ID: 18987663
[TBL] [Abstract][Full Text] [Related]
7. The role of chemokine receptor CXCR4 in lung cancer.
Gangadhar T; Nandi S; Salgia R
Cancer Biol Ther; 2010 Mar; 9(6):409-16. PubMed ID: 20147779
[TBL] [Abstract][Full Text] [Related]
8. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
9. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.
Pfeiffer M; Hartmann TN; Leick M; Catusse J; Schmitt-Graeff A; Burger M
Br J Cancer; 2009 Jun; 100(12):1949-56. PubMed ID: 19455144
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 antagonists suppress small cell lung cancer progression.
Taromi S; Kayser G; Catusse J; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
Oncotarget; 2016 Dec; 7(51):85185-85195. PubMed ID: 27835905
[TBL] [Abstract][Full Text] [Related]
11. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.
Otani Y; Kijima T; Kohmo S; Oishi S; Minami T; Nagatomo I; Takahashi R; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Fujii N; Kumanogoh A
FEBS Lett; 2012 Oct; 586(20):3639-44. PubMed ID: 22992418
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
14. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
16. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.
Wald O; Shapira OM; Izhar U
Theranostics; 2013; 3(1):26-33. PubMed ID: 23382783
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.
Ma N; Pang H; Shen W; Zhang F; Cui Z; Wang J; Wang J; Liu L; Zhang H
Int J Mol Med; 2015 Feb; 35(2):425-32. PubMed ID: 25504108
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of stromal CXCR4 impairs development of lung metastases.
D'Alterio C; Barbieri A; Portella L; Palma G; Polimeno M; Riccio A; Ieranò C; Franco R; Scognamiglio G; Bryce J; Luciano A; Rea D; Arra C; Scala S
Cancer Immunol Immunother; 2012 Oct; 61(10):1713-20. PubMed ID: 22399057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
